Log has written
MONDAY, JULY 21, 2008 1:54 AM IST
PTI
Mumbai: Pharmaceutical firm GlaxoSmithKline (GSK) Pharma has signed an agreement with Daiichi Sankyo India Pharma Limited (DSIPL) for jointly promoting the anti-hypertensive drug Olmesartan Medoxomil and its combination products.
GSK India has signed a co-promotion agreement with DSIPL, which is a subsidiary of Japan-based pharmaceutical company Daiichi Sanko Company Limited.
“This agreement comes close on the heels of our in-licensing agreement for Micafungin last week. Our strategy as laid out at the beginning of the year of in-licencing products in specific high growth therapeutic areas is being rolled out and is well on track,” GSK India managing director, Hasit Joshipura said.
Olmesartan is a $2 billion worth drug for Daiichii and is available in more than 50 countries worldwide, the company said in a filing to the Bombay Stock Exchange.
With this launch, Daiichi Sankyo India would mark its entry into India and pave the way for many more research products to be introduced in the future, Daiichi Sankyo India president V Vijayendran said.
Shares of GSK India were trading at Rs1,058, up 1.33% on the BSE in morning trade.
Tags - Find More Articles On:
 
SURJYA Said:


Assam Cancer Society& Rural Based Preventive Oncology Research Centre, (Cancer Awareness Campaign)NGO National Highway-37, P. O. Bokakhat-785 612. Assam. India. Registered under Assam Societies Registration Act. 1860; Registration No. 4780. Telephone : 091-3776-268377/268790, Fax No. 091-3776-268770. Email: surjya_bokakhat@rediffmail.com Please visit Website: http://www.karmayog.org/ngo/ACS. ---------------------------------------------------------------------------------------------------------- Subject: Please provide us fully equipped Mobile Cancer Hospitals on Wheels to save over 80% underserved cancer victims who are causing Global burden and we are exposed in critical situation at USA,Geneva ,UK and at many International forum as we are going to contribute about 50% cancer death Globally by 2025 from Assam North Eastern Region and Eastern India alone. So, we need drastic change to stop cancer death and to introduce early cancer detection schemes inmmediately. Respected Sir/Madam, That Sir, as stated above I am requesting your honour to control cancer effectively among underserved population of India and later it will add in GCCP(Global Cancer Control Programme). So, I have written this letter and few documents for your early response. Please see as below: (1) We need 9 nos. of fully equipped mobile vans now.AT THIS TIME. (2) One for Pathological Labs of all types. (3) One for all radiological image technology, (4) One for early detection equipments and internet,telemedicine, (5) One for Cancer education, (6) One for Radiotherapy, (7) One for Surgery, (8) One for ENT, (9) One for Gynacological diseases, (10) One for Breast Cancer Detection Programmes. (11) TEACHING AND RESEARCH MICROSCOPES 5 NOS. (12) FUND FOR RUNNING THE PROJECTS. (13) STAFF 140 NOS. WITH ALL SECTIONS SPECIALISTS. IT WILL BE A MOBILE CANCER HOSPITAL TO DETECT EVERY VILLAGE BASED CANCER VICTIMS. You kind co-operation will make the countr

Posted On 5/14/2008 5:45:46 PM